McGarrity Michael 4

What Happened

• Michael McGarrity, CEO of MDxHealth SA (ticker: MDXH), received two option award grants on June 1, 2026 totaling 942,200 option shares (329,800 and 612,400). The options have a strike price of $0.76 per share and the reported acquisition value is $0 (derivative awards reported as grants, code A).
• These are option grants (not exercises or open‑market purchases). They give the right to buy ordinary shares at $0.76, subject to vesting and any applicable conditions; no shares were sold or exercised in this filing.

Key Details

• Transaction date: June 1, 2026; Form 4 filed June 3, 2026 (timely filing).
• Grants: 329,800 options (Footnote F1) and 612,400 options (Footnote F2); combined 942,200 options; strike price $0.76 per share.
• Transaction type/code: Award/Grant (derivative) — Form 4 shows amount acquired as $0 because these are option grants.
• Shares owned after transaction: not specified in the supplied summary of the filing.
• Footnotes: F1 — options vest upon achievement of performance criteria evaluated by the Board at the end of the performance periods. F2 — options vest in three equal installments on each of the first three anniversaries of the grant date.
• Filing timeliness: Filed within two business days (not reported late).

Context

• These are grants of options (not an immediate purchase or sale). The options give the CEO the right to buy shares at $0.76 in the future if/when vested and exercised; exercising would require payment of the strike and may trigger tax withholding.
• Performance‑based and time‑based vesting schedules mean the awards vest over time or upon meeting company performance targets; such grants are common executive compensation to align management incentives with shareholder outcomes.